Moberg Pharma AB (publ) banner

Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 9.335 SEK 3.61% Market Closed
Market Cap: kr454.7m

Relative Value

The Relative Value of one MOB stock under the Base Case scenario is hidden SEK. Compared to the current market price of 9.335 SEK, Moberg Pharma AB (publ) is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MOB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MOB Competitors Multiples
Moberg Pharma AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Moberg Pharma AB (publ)
STO:MOB
438.8m SEK 35.1 -1.7 -7.7 -0.6
US
Eli Lilly and Co
NYSE:LLY
959.3B USD 14.7 46.5 31.3 33.3
US
Johnson & Johnson
NYSE:JNJ
585.3B USD 6.2 21.8 15.2 18.6
CH
Roche Holding AG
SIX:ROG
291.8B CHF 4.8 31.1 13.1 15.3
UK
AstraZeneca PLC
LSE:AZN
238.2B GBP 5.5 31.6 17.4 24.6
CH
Novartis AG
SIX:NOVN
242.2B CHF 5.5 22.2 13.7 17.6
US
Merck & Co Inc
NYSE:MRK
305.1B USD 4.7 16.7 10.4 12.2
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.3 13 9.5 11.2
US
Pfizer Inc
NYSE:PFE
151.4B USD 2.4 19.5 7.3 9.7
UK
GSK plc
XETRA:GS71
103.6B EUR 2.8 15.8 8 11.3
P/E Multiple
Earnings Growth PEG
SE
Moberg Pharma AB (publ)
STO:MOB
Average P/E: 24.2
Negative Multiple: -1.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.5
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.8
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.1
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
31.6
26%
1.2
CH
Novartis AG
SIX:NOVN
22.2
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13
7%
1.9
US
Pfizer Inc
NYSE:PFE
19.5
26%
0.7
UK
GSK plc
XETRA:GS71
15.8
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Moberg Pharma AB (publ)
STO:MOB
Average EV/EBITDA: 45.9
Negative Multiple: -7.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.3
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.4
11%
1.6
CH
Novartis AG
SIX:NOVN
13.7
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.4
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.3
-4%
N/A
UK
GSK plc
XETRA:GS71
8
2%
4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Moberg Pharma AB (publ)
STO:MOB
Average EV/EBIT: 98.9
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.3
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.6
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.3
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
24.6
24%
1
CH
Novartis AG
SIX:NOVN
17.6
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12.2
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.2
8%
1.4
US
Pfizer Inc
NYSE:PFE
9.7
-1%
N/A
UK
GSK plc
XETRA:GS71
11.3
12%
0.9